Previous close | 314.12 |
Open | 297.38 |
Bid | 300.23 x 900 |
Ask | 301.41 x 1000 |
Day's range | 295.79 - 304.98 |
52-week range | 215.96 - 335.83 |
Volume | |
Avg. volume | 1,089,712 |
Market cap | 80.303B |
Beta (5Y monthly) | 1.67 |
PE ratio (TTM) | 16.01 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.64 (0.84%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Robust Revenue Growth and Strategic Acquisitions Highlight the Quarter
HCA (HCA) delivered earnings and revenue surprises of 6.99% and 2.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.